Effects of Adriamycin-Cytoxan chemotherapy on hematological and electrolyte parameters among breast cancer patients
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1103013
Abstract: Background Adriamycin-Cytoxan (AC) is a common chemotherapy treatment for breast cancer (BC) patients. Its electrolyte and hematological adverse effects have not been addressed adequately. Objective This study aimed to assess the effect of AC on… read more here.
Keywords: adriamycin cytoxan; cancer patients; breast cancer; electrolyte parameters ... See more keywords